Ovid Therapeutics Inc. (OVID)
OVID Stock Price Chart
Explore Ovid Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze OVID price movements and trends.
OVID Company Profile
Discover essential business fundamentals and corporate details for Ovid Therapeutics Inc. (OVID) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 May 2017
Employees
23.00
Website
https://www.ovidrx.comCEO
Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
OVID Financial Timeline
Browse a chronological timeline of Ovid Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.14, while revenue estimate is $194.71K.
Earnings released on 13 Aug 2025
EPS came in at -$0.06 surpassing the estimated -$0.16 by +62.50%, while revenue for the quarter reached $6.27M , beating expectations by +10.13K%.
Earnings released on 13 May 2025
EPS came in at -$0.14 matching the estimated -$0.14, while revenue for the quarter reached $130.00K , beating expectations by +205.88%.
Earnings released on 11 Mar 2025
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $76.00K , missing expectations by -24.00%.
Earnings released on 12 Nov 2024
EPS came in at -$0.20 falling short of the estimated -$0.19 by -5.26%, while revenue for the quarter reached $173.00K , missing expectations by -7.73%.
Earnings released on 13 Aug 2024
EPS came in at $0.12 surpassing the estimated -$0.22 by +154.55%, while revenue for the quarter reached $169.00K , beating expectations by +141.43%.
Earnings released on 14 May 2024
EPS came in at -$0.17 surpassing the estimated -$0.23 by +26.09%, while revenue for the quarter reached $148.00K , beating expectations by +146.67%.
Earnings released on 8 Mar 2024
EPS came in at -$0.22 falling short of the estimated -$0.17 by -29.41%, while revenue for the quarter reached $141.56K , beating expectations by +135.94%.
Earnings released on 3 Nov 2023
EPS came in at -$0.16 surpassing the estimated -$0.18 by +11.11%, while revenue for the quarter reached $108.97K , beating expectations by +81.62%.
Earnings released on 4 Aug 2023
EPS came in at -$0.18 surpassing the estimated -$0.21 by +14.29%, while revenue for the quarter reached $75.00K , beating expectations by +50.00%.
Earnings released on 5 May 2023
EPS came in at -$0.19 falling short of the estimated -$0.18 by -5.56%, while revenue for the quarter reached $66.00K , beating expectations by +230.00%.
Earnings released on 13 Mar 2023
EPS came in at -$0.16 surpassing the estimated -$0.19 by +15.79%, while revenue for the quarter reached $46.28K .
Earnings released on 8 Nov 2022
EPS came in at -$0.17 surpassing the estimated -$0.21 by +19.05%, while revenue for the quarter reached $11.10K .
Earnings released on 9 Aug 2022
EPS came in at -$0.21 surpassing the estimated -$0.23 by +8.70%.
Earnings released on 10 May 2022
EPS came in at -$0.23 falling short of the estimated $1.17 by -119.66%, while revenue for the quarter reached $1.45M , beating expectations by +10.53%.
Earnings released on 15 Mar 2022
EPS came in at -$0.38 falling short of the estimated -$0.17 by -123.53%, while revenue for the quarter reached -$416.35M .
Earnings released on 10 Nov 2021
EPS came in at -$0.17 surpassing the estimated -$0.19 by +10.53%.
Earnings released on 16 Aug 2021
EPS came in at -$0.23 falling short of the estimated -$0.15 by -53.33%.
Earnings released on 13 May 2021
EPS came in at $2.53 surpassing the estimated $1.68 by +50.60%, while revenue for the quarter reached $208.38M , beating expectations by +22.67%.
Earnings released on 15 Mar 2021
EPS came in at -$0.34 falling short of the estimated -$0.31 by -9.68%, while revenue for the quarter reached $5.70M .
Earnings released on 12 Nov 2020
EPS came in at -$0.28 surpassing the estimated -$0.43 by +34.88%, while revenue for the quarter reached $6.91M , missing expectations by -18.18%.
OVID Stock Performance
Access detailed OVID performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.